https://scholars.lib.ntu.edu.tw/handle/123456789/470191
標題: | The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers | 作者: | CHIUN-SHENG HUANG SUNG-HSIN KUO HUANG-CHUN LIEN Yang S.-Y. You S.-L. Shen C.-Y. CHING-HUNG LIN YEN-SHEN LU KING-JEN CHANG |
公開日期: | 2008 | 卷: | 13 | 期: | 7 | 起(迄)頁: | 751-760 | 來源出版物: | Oncologist | 摘要: | Purpose. Given the critical role of the CYP19 gene, encoding aromatase, in estrogen synthesis and the association of the estrogen level with its TTTA repeat polymorphism, the potential influence of this polymorphism on breast cancer survival, and hence management, deserves further study. Methods. Genotyping for the CYP19 TTTA repeat polymorphism was performed on 482 stage I-II and operable stage III Taiwanese breast cancer patients. Patients with more than seven TTTA repeats in either allele of CYP19 were defined as having the long allele. We correlated clinical variables and CYP19 genotypic polymorphism with outcome. Results. In hormone receptor (HR)-positive breast cancers, premenopausal patients with the long allele of the CYP19 polymorphism had a significantly higher overall survival (OS) rate (8-year, 89% versus 68%; p = .003) than those without it. This difference was further demonstrated by a multivariate analysis (OS hazard ratio, 1.53; p = .041). In postmenopausal women or patients with HR-negative breast cancer, there was no significant difference in OS between patients with or without the long allele. In premenopausal women with HR-positive cancers, adequate intensity adjuvant chemotherapy did not achieve a greater OS rate than suboptimal chemotherapy in patients with the long allele, but it resulted in a significantly higher OS rate (p = .011) than suboptimal chemotherapy in women without the long allele. Conclusion. The CYP19 TTTA repeat polymorphism is associated with survival in premenopausal women, but not in postmenopausal women, with HR-positive breast cancers. Premenopausal women with the long allele have a greater survival rate and may not gain benefit from adjuvant chemotherapy. ?AlphaMed Press. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-48749117418&doi=10.1634%2ftheoncologist.2007-0246&partnerID=40&md5=0cf714822c9ed6189a77ae59aa3532d2 https://scholars.lib.ntu.edu.tw/handle/123456789/470191 |
ISSN: | 1083-7159 | DOI: | 10.1634/theoncologist.2007-0246 | SDG/關鍵字: | antineoplastic agent; aromatase; estrogen receptor; progesterone receptor; tamoxifen; adult; aged; article; Asian; breast cancer; cancer adjuvant therapy; cancer patient; cancer survival; female; genetic polymorphism; genotype; human; major clinical study; multivariate analysis; overall survival; premenopause; priority journal; prognosis; survival rate; survival time; Adult; Aged; Aromatase; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Humans; Introns; Kaplan-Meiers Estimate; Microsatellite Repeats; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Postmenopause; Premenopause |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。